ARTICLE SUMMARY:
With roots in some of the original tissue-based cardiovascular valves, enVVeno aims to solve a lesser understood vascular issue.
Before enVVeno Medical (Nasdaq: NVNO) was known as such, it was known as Hancock Jaffe Laboratories. Co-founder Warren Hancock, who left Edwards Laboratories (now Edwards Lifesciences) in the early 1970s called Hancock Jaffe was a developer of one of the first porcine tissue-based heart valves. CEO Rob Berman joined the company six years ago and took it public with a small IPO, subsequently rebuilding the company with a new board of directors and senior management team.
